Inosine pranobex

When ATH:
J05AX05

Pharmacological action.
Immunostimulatory, antiviral.

Application.

Viral infections in patients with normal and impaired immune systems, incl. disease, caused by viruses Herpes simplex types 1 and 2, Varicella zoster (including chickenpox), Measles virus, mumps, Cytomegalovirus, Epstein - Barr virus; viral bronchitis; acute and chronic viral hepatitis B and C; disease, caused by human papillomavirus; subacute sclerosing panencephalitis; chronic urinary tract infections and respiratory systems; prevention of infections in stressful situations; convalescence postoperative patients and people, have had severe disease; immunodeficiency states; radiotherapy.

Contraindications.

Hypersensitivity, hyperuricemia, renal failure, nephrotoxicity- and urolithiasis, the tendency to arrhythmia, autoimmune diseases, pregnancy, lactation.

Pregnancy and breast-feeding.

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects.

From the nervous system and sensory organs: dizziness, a feeling of fatigue, headache.

From the digestive tract: early treatment dyspepsia (nausea, vomiting, diarrhea).

Other: transient increase in uric acid in the blood and urine, allergic reactions, in some cases - increase in liver enzymes, arthralgia.

Cooperation.

Immunosuppressants reduce the effectiveness (Avoid simultaneous use).

Dosing and Administration.

Inside, the usual daily dose for adults - 50 mg / kg (if necessary, increase the dose to 100 mg / kg) 3-4 reception; children - 50-100 mg / kg, divided into equal parts 3-4. The usual course of treatment 5-10 days, in severe cases - up 15 days, If necessary, repeat. Long-term treatment is carried out under the supervision of a physician.

Precautions.

The need for periodic determination of uric acid in the blood and urine. With prolonged use, continuous monitoring of liver function, kidney, peripheral blood.